Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia

被引：19

作者：

Cicero A.F.G. ^{[1
]}

Reggi A. ^{[1
]}

Parini A. ^{[1
]}

Morbini M. ^{[1
]}

Rosticci M. ^{[1
]}

Grandi E. ^{[1
]}

Borghi C. ^{[1
]}

机构：

[1] Medical and Surgical Sciences Department, University of Bologna, S. Orsola-Malpighi Hospital, 40138 Bologna, Via Albertoni

来源：

High Blood Pressure & Cardiovascular Prevention | 2014年 / 21卷 / 3期

关键词：

Berberine; Hypercholesterolemia; Nutraceuticals; Oestroprogestins; Polycystic ovary syndrome; Red yeast rice;

D O I：

10.1007/s40292-014-0052-5

中图分类号：

学科分类号：

摘要：

Introduction: One of the most frequent side effect of oral contraceptives use is a stable alteration of the lipid profile. This could be even more relevant in women affected by polycystic ovary syndrome (PCOS). Aim: Considering the importance of a balanced lipid profile in cardiovascular prevention and that the exposure to the drugs could be many years long, our aim was to investigate the possible beneficial effect of a largely tested low-dosed combined lipid-lowering nutraceutical on dyslipidemias induced by oestroprogestins prescribed to young women for different indications. Methods: We prospectively enrolled 84 patients in primary cardiovascular disease prevention, with low estimated cardiovascular disease risk (<5 % according to the ESC/EAS guidelines), and LDL-C increased above normal value (LDL-C >130 mg/dL) after the use of at least two different oral oestroprogestins treatments. Forty-four women were prescribed oral oestroprogestins for PCOS, while 40 for pure contraception. The tested nutraceutical contained berberine 500 mg/tab and monacolins 3 mg/tab was prescribed to all enrolled patients, associated the previously prescribed standard lipid-lowering diet. Results: After 3 months of nutraceutical treatment, we observed a significant improvement in BMI (-1.5 ± 0.8 %, p < 0.001), FPG (-6.9 ± 5.8 %, p < 0.001), HOMA index (-3.5 ± 5.6 %, p < 0.001), TC (-20.1 ± 6.6 %, p < 0.001), LDL-C (-25.3 ± 8.9 %, p < 0.001), HDL-C (+14.1 ± 2.2 %, p < 0.001), TG (-29.9 ± 25.2 %, p < 0.001) and hsCRP (-2.5 ± 2.4 %, p = 0.019). Similar results have been obtained even repeating the analysis by subgroups, beyond hsCRP that significantly improved in PCOS patients compared to both the baseline and the non-PCOS group. Conclusion: It appears that the tested combined lipid-lowering nutraceutical is able to equally improve lipid metabolism in oral contraceptive induced hypercholesterolemia in women affected or not by PCOS. © 2014 Springer International Publishing.

引用

页码：221 / 226

页数：5

共 30 条

[1]

Trussell J., Contraceptive failure in the United States, Contraception, 83, 5, pp. 397-404, (2011)

[2]

Streuli I., De Ziegler D., Santulli P., Marcellin L., Borghese B., Batteux F., Chapron C., An update on the pharmacological management of endometriosis, Expert Opin Pharmacother, 14, 3, pp. 291-305, (2013)

[3]

Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O., The prevalence and features of the polycystic ovary syndrome in an unselected population, Journal of Clinical Endocrinology and Metabolism, 89, 6, pp. 2745-2749, (2004)

[4]

Soares G.M., Vieira C.S., De Paula Martins W., Dos Reis R.M., De Sa M.F., Ferriani R.A., Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome, Int J Clin Pract, 63, 1, pp. 160-169, (2009)

[5]

Kaplan B., Desogestrel, norgestimate, and gestodene: The newer progestins, Ann Pharmacother, 29, 7-8, pp. 736-742, (1995)

[6]

Wiegratz I., Stahlberg S., Manthey T., Sanger N., Mittmann K., Palombo-Kinne E., Mellinger U., Lange E., Kuhl H., Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use, Contraception, 81, 1, pp. 57-61, (2010)

[7]

Barreiros F.A., Guazzelli C.A.F., Barbosa R., Torloni M.R., Barbieri M., Araujo F.F., Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: Effects on lipid metabolism, Contraception, 84, 2, pp. 155-159, (2011)

[8]

Wahl P., Walden C., Knopp R., Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol, New England Journal of Medicine, 308, 15, pp. 862-867, (1983)

[9]

Godsland I., Crook D., Simpson R., Proudler T., Felton C., Lees B., Anyaoku V., Devenport M., Wynn V., The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism, N Engl J Med, 323, 20, pp. 1375-1381, (1990)

[10]

Crook D., Godsland I.F., Wynn V., Oral contraceptives and coronary heart disease: Modulation of glucose tolerance and plasma lipid risk factors by progestins, Am J Obstet Gynecol, 158, 6 PART 2, pp. 1612-1620, (1988)

← 1 2 3 →